Pelvic Inflammatory Disease

Last updated: February 22, 2025
Table Of Contents

Pelvic Inflammatory Disease

Pelvic inflammatory disease is a subacute to chronic infectious disease that affects the upper female reproductive tract (cervix, uterus, fallopian tubes, ovaries) and/or peritoneum. The most common causative organisms are C. trachomatis and Neisseria gonorrhoeae, but most cases can be polymicrobial (involving anaerobes hence empiric antibiotics should be broad-spectrum).

Infertility is a common complication of PID. Infections may spread into the peritoneum and involve peri-hepatic structures (Fitz-Hugh Curtis Syndrome – can be confused as gallbladder disease if there is RUQ pain). Diagnosis is clinical. Most patients are treated outpatient with antibiotics. The threshold for diagnosis of PID is low. Empiric antibiotics can be initiated at presentation if there is suspicion. Screening for lower genital tract chlamydial infection in young and high-risk individuals is recommended to reduce the incidence of PID, and asymptomatic disease in patients who return positive should be treated.

  • Risk factors
    • Multiple sex partners/ new sexual partner
    • Age <25 years
    • Unprotected sex
    • History of STD (chlamydia, gonorrhea)
    • Younger age at first intercourse
    • Substance abuse
    • Lower socioeconomic status
    • Intrauterine contraceptive device (IUD) use
    • Instrumentation of the uterus such as surgical termination of pregnancy
    • Post-partum endometritis.
  • Protective factors
    • Barrier contraception
    • Combined oral contraceptive pill
    How are COCPs protective?Menstrual blood may act as a cultural medium, facilitating PID’s development. The average amount of menstrual blood a woman loses each month is decreased when using COCPs.
  • Patient history
    • Young woman of reproductive age
    • Unprotected intercourse with multiple partners
  • Signs and symptoms
    • Lower abdominal pain
      • Acute and constant
      • Dull and crampy
      • Usually non-severe
      • Bilateral
      • Associated with menstruation (begins a few days after menses)
    • Mucopurulent vaginal discharge
    • Deep dyspareunia
    • Post-coital vaginal bleeding (inflammation makes tissue more friable)
    • Fever
    • Nausea and vomiting
    • Irregular and/or more painful menses.
  • Physical examination
    • Cervical motion tenderness
    • Uterine tenderness
    • Global uterine or adnexal tenderness (most sensitive finding)
    • Mucopurulent discharge
    • Erythematous inflammed cervix
    • Fever +/- other systemic symptoms
    • RUQ pain/ tenderness (Fitz-Hugh-Curtis syndrome)
    • Rebound tenderness and guarding (in tubo-ovarian abscess or generalized peritonitis)
  • Differentials
    • Ectopic pregnancy
    • Endometriosis
    • Ovarian torsion
    • Ovarian cysts
    • Tubo-ovarian abscess
    • Urinary tract infection
    • Interstitial cystitis
    • Appendicitis
  • Clinical criteria for diagnosis
    • Cervical motion tendernes or,
    • Uterine tenderness, or
    • Adnexal tenderness
    Additional criteria may include PO temperature > 38.3 degrees celsius, abnormal cervical or vaginal mucopurulent discharge, abundant WBCs on microscopy of vaginal secretions, elevated ESR or CRP, and documented chlamydial or gonorrhoeal infection
  • Investigations
    • Qualitative B-hCG: rule out ectopic pregnancy
    • Culture and microscopy of vaginal secretions
      • Tests for gonorrhoea and chlamydia.
    • Transvaginal sonography or CT-scan: to rule out tubo-ovarian abscess, particularly in more ill-appearing patients and those who do not respond to outpatient treatment
    • Liver Function Tests: if there is RUQ pain
  • Outpatient treatment
    • IM Ceftriaxone 500mg single-dose + PO doxycycline 100mg q12h for 14 days
    • May add PO Metronidazole 500mg q12 for 14 days (to target anaerobes)
    • Azithromycin single-dose if allergic to cephalosporins
  • Indications for inpatient treatment (IV antibiotics)
    • Adolescent
    • Cannot complete a course of oral antibiotics (including nausea or vomiting that precludes oral treatment)
    • Failed outpatient treatment
    • Pregnant patient
    • Tubo-ovarian abscess (large abscesses will need to be drained)
    • Severe disease (high fever, toxic appearing)
    • Generalized peritonitis
    • Drug abuse
    • Recent intrauterine instrumentation
    • WBCs > 15,000
  • Inpatient treatment
    • IV cefoxitin 2g q 6h + doxycycline 100mg q12 h
    • Clindamycin or metronidazole for anaerobic coverage
    • Transition to oral antibiotics and discharge 24-48 hours after clinical improvement with IV therapy
    • If treatment fails perform imaging to rule out tubo-ovarian abscess
  • Treatment of tubo-ovarian abscess
    • IV antibiotics: abscess 4-6 cm can be managed with antibiotics alone
    • Percutaneous drainage (especially for large abscess > 10 cm)
    • Surgical drainage with salpingo-oophorectomy (rarely requires total hysterectomy with bilateral salpinho-oophorectomy)
  • Indications for surgical drainage of a tubo-ovarian abscess
    • Sepsis
    • Drainage is unfeasable
    • Patient fails antibiotics
    • Rupture of abscess
  • Complications of pelvic inflammatory disease
    • Ectopic pregnancy
    • Infertility
    • Fitz-Hugh-Curtis syndrome
    • Chronic pelvic pain
    • Tubo-ovarian abscess.
Ultrasound showing a 4 x 4cm complex cyst in the left ovary consistent with a tubo-ovarian abscess
Per-hepatic adhesions seen on laparoscopy in Fitz-hugh curtis syndrome 
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *